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Abstract
Oncolytic viruses (OVs) represent a relatively novel anti-cancer modality. Like other new cancer treatments, effective OV
therapy will likely require combination with conventional treatments. In order to design combinatorial treatments that work
well together, a greater scrutiny of the mechanisms behind the individual treatments is needed. Sindbis virus (SV) based
vectors have previously been shown to target and kill tumors in xenograft, syngeneic, and spontaneous mouse models.
However, the effect of SV treatment on the immune system has not yet been studied. Here we used a variety of methods,
including FACS analysis, cytotoxicity assays, cell depletion, imaging of tumor growth, cytokine blockade, and survival
experiments, to study how SV therapy affects Natural Killer (NK) cell function in SCID mice bearing human ovarian
carcinoma tumors. Surprisingly, we found that SV anti-cancer efficacy is largely NK cell-dependent. Furthermore, the
enhanced therapeutic effect previously observed from Sin/IL12 vectors, which carry the gene for interleukin 12, is also NK
cell dependent, but works through a separate IFNc-dependent mechanism, which also induces the activation of peritoneal
macrophages. These results demonstrate the multimodular nature of SV therapy, and open up new possibilities for
potential synergistic or additive combinatorial therapies with other treatments.
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Introduction
Research into the utilization of oncolytic viruses (OVs) for cancer
therapy has increased exponentially in the last few years. A variety
of viruses have been used in these studies, including adenovirus,
vaccinia virus, vesicular stomatitis virus, herpes simplex virus, and
others (reviewed in [1]). OVs are unique in their ability to
specifically kill tumor cells while sparing non-tumor cells, both in
vitro and in various mouse models. Tumor specificity is achieved in
differentways,includingbindingtoreceptorsthat areoverexpressed
in cancer cells, utilizing cancer-specific promoters, and taking
advantage of defective anti-viral responses in tumor cells. Clinical
studies have demonstrated OV safety, but the efficacy of OV
therapy in human patients still needs to be determined.
In the first few years of OV research, much of the focus was on
optimizing tumor targeting or viral replication in tumors. As a
result, the immune response to the virus was seen merely as an
obstacle to effective OV treatment. However, if the immune
response to the virus could be redirected against the tumor, it
could prove to be therapeutically beneficial [2]. Traditionally,
cancer immunotherapy involved using specific immune modula-
tors (e.g. cytokines or cells) to promote an anti-cancer immune
response. As intracellular pathogens, viruses stimulate a variety of
immune modulators and effector cells, which could also act against
tumors. In addition, genetically engineered OVs can deliver
specific immune-stimulating cytokines into the tumor site [3], thus
limiting the side effects associated with systemic administration of
cytokines [4], and potentially synergizing with virally induced
cytokines.
Murine models for studying OV cancer therapy can be divided
into two general groups: immunocompetent mice bearing
syngeneic (spontaneous or implanted) tumors [5], and immuno-
deficient mice (typically SCID mice, which lack T and B cells, or
nude mice, which lack T cells) implanted with human xenograft
tumors [6,7,8]. An increasing number of studies using immuno-
competent mouse models have demonstrated that immune cells
(particularly NK cells and T cells) play an important role in the
therapeutic effect induced by the virus [2,9,10]. However, far less
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mouse models of OV therapy. Indeed, models using immunode-
ficient mice have often been considered to essentially lack immune
cell activity, and as a result, effective OV treatment in these
models was attributed to direct tumor killing. However, immuno-
deficient mice still retain important components of the innate
immune response, including NK cells, macrophages, and
neutrophils [11]. Given the role of immune cells in OV therapy
in immunocompetent mice, the mechanism behind OV efficacy in
immunodeficient mouse models should also be re-evaluated.
NK cells have evolved to recognize and kill abnormal host cells,
including virally infected cells and tumor cells. In addition,
activated NK cells can secrete cytokines that could influence the
course of the immune response to a disease [12]. As such, they are
uniquely interesting cells in the context of OV therapy, because
they represent a ‘‘double bridge,’’ linking tumor cells to the more
immunogenic OV-infected cells, while also linking the innate
immune response to the potentially more potent adaptive immune
response. One goal of OV therapy should therefore be to activate
the cytotoxic and regulatory functions of NK cells against cancer.
Sindbis virus, an alphavirus with a positive single-stranded RNA
genome, has several advantages that make it a good candidate for
cancer therapy. In nature, SV does not cause severe disease in
humans. Furthermore, the SV lifecycle does not have a DNA
phase, so there is no risk of genomic integration. SV is believed to
target tumors through interactions with the high-affinity laminin
receptor [13], which is overexpressed in many cancers, though
additional factors are likely also involved [14]. In our lab, we use a
replication deficient form of SV, in which the structural proteins
have been removed [15], further enhancing its safety. Replication
defective SV vectors can also carry therapeutic genes into the
tumor environment to generate a bystander therapeutic effect
[16], in addition to inducing apoptosis in infected cancer cells [17].
Finally, because SV is a blood-borne pathogen, it can be injected
systemically to target metastatic tumors [18]. Previous studies
using SV vectors have demonstrated that they can target tumors,
and have a strong therapeutic effect in various mouse models,
including xenograft SCID models, syngeneic immunocompetent
models, and a spontaneous tumor model [18]. Experiments using
baby hamster kidney tumors in SCID/beige mice have pointed to
a potential therapeutic role for NK cells [17]. Additionally, SV
vectors carrying IL12, a known NK cell activator and immune
modulator, have an enhanced therapeutic effect in SCID mice
bearing human ovarian cancer tumors [18].
In this study, we show for the first time that SV vectors can activate
NK cells in the peritoneum of SCID mice bearing intraperitoneally
(i.p.) growing ES-2 cells, a human ovarian carcinoma cell line.
Surprisingly, we also found that NK cell activation is critically
important for effective SV treatment in this model. In addition, we
found that the therapeutic effect of Sin/IL12, which further improves
mouse survival, is dependent on both the cytotoxic and regulatory
functionsofNKcells.Theregulatoryfunction,whichisdependenton
IFNc, also results in the upregulation of MHC class II on
macrophages, demonstrating a shift towards the anti-cancer M1
phenotype. Taken together, our results show an important new
mechanism for SV anti-cancer efficacy in SCID mice, with
implications for future SV clinical studies and treatment designs.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Institute of
Animal Care and Use Committee at New York University
Medical Center (protocol number 081115-03).
Mice
6-12-week-old female C.B-17-SCID and C.B-17-SCID beige
mice were purchased from Taconic (Germantown, NY). In some
experiments, we used SCID mice from our own colony, which
were generated by breeding C.B-17-SCID mice with Ces1c
e
Foxn1
nu/J mice (The Jackson Laboratory), and were selected for
the absence of T and B cells, and for a deficiency in plasma
esterase activity, which was needed for a separate study. No
noticeable difference in NK cell activation was observed between
SCID mice from our colony and C.B-17-SCID mice, and key
experiments (FACS, NK depletion, etc.) were done at least once
with C.B-17-SCID mice.
Cell lines
Baby hamster kidney (BHK), ES-2 cells, and YAC-1 cells were
obtained from the American Type Culture Collection. BHK cells
were maintained in minimum essential a-modified media (aMEM,
Mediatech, Inc.) with 10% fetal calf serum (FCS). ES-2 cells were
cultured in McCoy’s 5A medium (Mediatech) supplemented with
10% FCS. ES-2/Fluc cells (referred to as ES-2 cells here), which
express firefly luciferase (Fluc), for noninvasive bioluminescent
imaging, were derived from the ES-2 cell line by stable
transfection of a plasmid, pIRES-2-Fluc/EGFP, as previously
described [18]. YAC-1 cells were maintained in DMEM
(Mediatech) containing 4.5 g/l glucose and supplemented with
10% FCS. All basal media were supplemented with 100 mg/mL of
penicillin-streptomycin (Mediatech) and 0.5 mg/mL of amphoter-
icin B (Mediatech).
Sindbis Vector Production
Sindbis vectors (Sin/LacZ and Sin/IL12) were produced as
previously described [17]. Briefly, plasmids carrying the replicon
(SinRep-LacZ or SinRep-IL12) or DHBB helper RNAs were
linearized with XhoI. In vitro transcription was performed using the
mMessage mMachine RNA transcription kit (Ambion). Helper
and replicon RNAs were then electroporated into BHK cells and
incubated at 37uCi naMEM supplemented with 10% FCS. After
12 hours, the media was replaced with OPTI-MEM (GIBCO-
BRL) supplemented with CaCl2 (100 mg/l) and cells were
incubated at 37uC. After 24 hours, the supernatant was collected,
centrifuged to remove cellular debris, and frozen at 280uC.
Vectors were titered as previously described [17].
FACS analysis
Anti-mouse antibodies (Abs) were purchased from ebioscience,
San Diego, CA: Anti-CD45 PE-Cy7, anti-CD122 FITC, anti-
CD335 (NKp46) FITC, anti-CD314 (NKG2D) PE, anti-CD178
(Fas Ligand) PE, anti-CD253 (TRAIL) PE, anti-CD49b (DX5)-PE
anti-CD69 APC, anti-Ly-6C PerCP-Cy5.5, anti-Ly-6G (Gr-1)
APC-eFluorH 780, anti-F4/80 Antigen PE, anti-MHC Class II (I-
A/I-E) Alexa FluorH 700.
For analysis of peritoneal cells with FACS, mice were
euthanized, and their peritoneum was washed with 5 ml cold
HBSS (Mediatech). Samples were then stained with various Abs,
washed twice with HBSS, and analyzed using an LSR II machine
(BD Biosciences, San Jose, CA). Data was analyzed using FlowJo
(Tree Star, Inc.). NK cells were identified as CD122+ SSC (side
scatter) low, or NKp46+ SSC low cells. Macrophages were
identified as F4/80+ FSC (forward scatter) high cells. Monocytes
were identified as Ly-6C-high cells, after excluding macrophages.
Neutrophils were identified as Gr-1-high cells after excluding
macrophages and monocytes (which can upregulate Gr-1 when
activated). Cell quantification: Peritoneal NK cells were quantified
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0.5 mL of the original peritoneal 5 mL wash, and multiplying this
number by 10. Other cells were quantified in a similar manner.
NK cell cytotoxicity assay
ES-2-bearing mice were treated on days 4, 5 and 6 after ES-2
inoculation with Sin/LacZ or media. On day 7, single cell
suspensions were obtained from Sin/LacZ-treated mice by
washing the peritoneum with 7 ml ice-cold HBSS, or from
mechanically separated spleens of mock-treated mice. NK cells
were isolated from these samples using the MoFlo cell sorter
(DakoCytomation, Ft. Collins, CO) by staining NK cells with anti-
CD49b PE, and staining non-NK myeloid cells with anti-Gr-1
APC-eFluorH 780. NK cells were characterized and isolated as
small (low FSC) and relatively rounded (low SSC) cells that were
positive for CD49b, and low for Gr-1. The purity of the NK cell
population was verified using FACS analysis on the LSR II, and
was confirmed to be over 80% NK cells in both samples.
The cytotoxicity of NK cells was assessed using the CytoTox
96H Non-Radioactive Cytotoxicity Assay kit (Promega) according
to the manufacturer’s instructions. Briefly, YAC-1 cells were
counted and 10,000 cells/well were added to the assay plate. NK
cells were added to triplicate wells in the following ratios, (NK
cells: YAC-1 cells) 5:1, 1.25:1, 0.312:1, 0.078:1 and 0.019:1. Plates
were centrifuged at 2506g for 4 minutes at 4uC and then
incubated for 4 hours at 37uC. Controls for spontaneous effector
cell release (NK cells alone) and spontaneous target cell release
(YAC-1 cells alone) were processed in parallel. Target maximum
release was also assayed in parallel. Samples were treated similarly,
cells were incubated at 37uC for 3 hours then lysis solution was
added and cells were incubated for an additional hour at 37uC.
Samples were centrifuged at 2506g for 4 minutes at 4uC. A 50 ml
volume of supernatant was transferred to a flat bottom plate and
substrate mix was added. Samples were incubated for 30 minutes
at room temperature and then stop solution was added. The plate
was read at 490 nm using an ELx800 plate reader (Biotek
Instruments, Inc.). Cytotoxicity was calculated according to the
manufacturer’s instructions.
Therapeutic efficacy experiments (imaging and survival)
Treatment started on day 3 or 4 after i.p. inoculation of 1610
6
ES-2 cells in 0.5 mL PBS. Sin/LacZ, Sin/IL12 treatments (,10
7
plaque-forming units in 0.5 mL of OptiMEM I), and mock
treatments (0.5 mL of OptiMEM I supplemented with 100 mg/l
CaCl2) were administered i.p. 4 times a week for 2 weeks, for a
total of 8 treatments. Therapeutic efficacy was monitored in two
ways: tumor luminescence, and survival. Noninvasive biolumines-
cent imaging was done using the IVISH Spectrum imaging system
(Caliper Life Science, Inc.), and tumor growth was quantified
using the Living ImageH 3.0 software (Caliper Life Science), as
previously described [18]. Survival was monitored and recorded
daily.
NK cell depletion
NK cells were depleted using either anti-CD122 (clone TM-b1;
BioXcell, West Lebanon, NH), or anti-Asialo Gm1 (Wako, Dallas,
Tx). In both cases, Abs were injected i.p. starting 1 day before the
first Sindbis treatment, and were then injected every 2–3 days for 2
weeks (for therapeutic experiments), or less (for FACS experi-
ments). For the anti-CD122 experiment, 20 mg Ab in 0.2 mL PBS
per mouse was used in the first injection, and 10 mg Ab in 0.2 mL
PBS for the subsequent injections. For the anti-Asialo Gm1
experiment, 50 ml Ab was diluted into 0.2 mL PBS per mouse.
Control groups were injected with matched isotype control Ab,
with PBS, or were left untreated.
Sin/LacZ + syngeneic NK cell combination therapy
Spleens from tumor free and untreated SCID mice were
mechanically separated, and NK cells were isolated from them
using the MoFlo cell sorter by staining NK cells with anti-CD49b
PE, and staining non-NK myeloid cells with anti-Gr-1 APC-
eFluorH 780. NK cells were characterized and isolated as small
(low FSC) and relatively rounded (low SSC) cells that were positive
for CD49b, and low for Gr-1. The purity of the NK cell
population was verified using FACS analysis on the LSR II, and
was confirmed to be over 80% NK cells. 6610
5 NK cells in
0.2 mL HBSS were injected a single time, retro-orbitally, into ES-
2-bearing mice 4 days after tumor inoculation, and 2 h before the
first Sin/LacZ treatment. Control mice (mock or Sin/LacZ-
treated) did not receive any NK cells. Mice were treated with
Sindbis or media 4 times a week for 2 weeks, and tumor
progression was determined by imaging and by monitoring
survival, as in previous therapeutic efficacy experiments.
IFNc ELISA
For detection of peritoneal IFNc, mice were euthanized, and
their peritoneum was washed with 2 ml of cold HBSS (Media-
tech). IFNc levels in the peritoneum were determined using Mouse
IFNc ELISA Kit II (BD Biosciences) according to the manufac-
turer’s instructions. In one experiment, the peritoneum was
washed with 5 ml rather than 2 ml, so the final concentration in
this experiment was normalized to the other experiments by
multiplying the concentration by 2.5.
IFNc Block
IFNc was blocked using XMG1.2 (BioXcell), a monoclonal
anti-IFNc Ab. 250 mg Ab in 0.2 mL PBS was injected i.p. 30
minutes before the first Sindbis treatment, and then every 2–3 days
for 2 weeks (for therapeutic experiments) or less (for FACS
experiments). Control mice were injected with Rat IgG isotype
control Ab, or were left untreated.
Statistics
For FACS, IVIS imaging, ELISA, and survival experiments,
student t tests (2-tailed), 2-way ANOVA, or Kaplan-Meier log-
rank test were done, using PrismH 4 for Macintosh (GraphPad
Software, Inc., La Jolla, CA). Error bars shown represent the
SEM.
Results
Sin/LacZ induces the influx of NK cells into the
peritoneum of ES-2-bearing mice
We have previously shown that Sin/LacZ, a SV vector carrying
the gene for b-galactosidase, targets ES-2 tumors in vivo, and has a
therapeutic effect in SCID mice bearing these tumors [19]. In this
study, we used ES-2 cells carrying firefly luciferase (ES-2/Fluc),
which have previously been used to monitor tumor growth [18].
For simplicity, ES-2/Fluc cells will be referred to as ES-2 cells
throughout this study.
First, we wanted to see if SV treatment induces an immune
response in SCID mice bearing ES-2 tumors. To determine the
effect of SV treatment on the immune cell populations in the
peritoneum, mice were treated i.p. with Sin/LacZ on days 4 and 5
after i.p. ES-2 inoculation. On day 6, the mice were euthanized,
and cells harvested from the peritoneal cavity were analyzed by
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influx of NK cells in response to the treatment. There was also an
influx of monocytes, while the number of macrophages and
neutrophils was not significantly affected by the treatment at 48 h
(Fig. 1A).
Analysis of the kinetics of changes in the peritoneal immune cell
populations in response to the treatment revealed that the influx of
NK cells into the peritoneum started within a few hours after the
first Sin/LacZ injection, and that the increased NK cell population
was sustained (though slightly reduced) throughout a 2-week
treatment regimen (Fig. 1B). In contrast, the increase in monocytes
in response to the treatment was short-lived, with the monocyte
population in Sin/LacZ-treated mice being higher than in mock-
treated mice only in the first 1–2 days (Fig. 1B). Interestingly, the
neutrophil population steadily increased in mock-treated mice, but
was stable (and much lower) in Sin/LacZ-treated mice, in which
there was only a minor early influx of neutrophils in the first hours
after the first treatment (Fig. 1B). A detailed analysis of the
function of these peritoneal neutrophils is beyond the scope of this
study. Lastly, the total macrophage population was only slightly
affected by the treatment.
In this study, we focus on NK cells, as they are the only
peritoneal cell population that was consistently higher in Sin/
LacZ-treated mice, and in which a higher population correlated
with effective treatment. Notably, the NK cell population did not
change in the Mock-treated mice (Fig. 1B), and the ES-2 tumors
themselves did not induce a significant influx of NK cells into the
peritoneum (data not shown). To determine if ES-2 cells were
involved in the SV-induced influx of NK cells, we repeated the
experiment shown in Fig 1.A in tumor-free mice. The results show
that Sin/LacZ can induce the influx of NK cells even in the
absence of ES-2 cells (Fig. S1). In all subsequent experiments, we
used ES-2 bearing mice rather than tumor-free mice, in order to
reproduce the therapeutic conditions.
Sin/LacZ induces the activation of NK cells in the
peritoneum
In order to determine if the NK cells that influx into the
peritoneum in response to the treatment were activated, peritoneal
NK cells from mock-treated and Sin/LacZ-treated ES-2-bearing
mice were analyzed using multicolor FACS analysis. CD122+ SSC
low NK cells were gated as shown in Fig 1.A, and the activation
level of these cells was examined.
We observed an increase in the size and granularity of
peritoneal NK cells from Sin/LacZ-treated mice, indicating the
accumulation of cytotoxic granules in these cells (Fig. 2A). We also
observed that the early activation marker CD69 is expressed on
peritoneal NK cells from Sin/LacZ-treated mice, an expression
that peaks at around 24 h after the first treatment (Fig. 2B), and
that NKG2D, a known activating receptor associated with
perforin-mediated NK cell cyotoxicity [20] is upregulated in
response to the treatment (Fig. 2C). However, Trail and FasL,
which are upregulated on NK cells in response to some stimuli
[21,22] are not upregulated in response to Sin/LacZ treatment
(Fig. 2C).
In order to confirm that peritoneal NK cells from Sin/LacZ-
treated mice were activated, we tested their ability to lyse YAC-1
cells, a mouse T cell lymphoma commonly used in NK
cytotoxicity assays. We found that compared to spleen NK cells
from mock-treated mice, peritoneal NK cells from Sin/LacZ-
treated mice had an enhanced capacity to kill YAC-1 cells
(Fig. 2D). Spleen NK cells were used as the baseline rather than
peritoneal NK cells because there were too few NK cells in the
peritoneum of mock-treated mice.
The efficacy of Sin/LacZ treatment is greatly reduced in
SCID/beige mice
Next we wanted to determine if the NK cells that are activated
and influx into the peritoneum in response to Sin/LacZ influence
the efficacy of Sin/LacZ anti-cancer treatment. To do this, ES-2-
bearing SCID mice and SCID/beige mice, which have a
deficiency in NK cell cytotoxicity, were treated with Sin/LacZ
or with media (mock). Tumor growth was determined by
measuring tumor luminescence using the IVIS imaging system,
and survival was monitored daily. We found that tumors did not
grow faster in mock-treated SCID/beige mice compared to
mock-treated SCID mice (Fig. 3A, B and C), indicating that NK
cells did not affect tumor growth in mock-treated mice. These
results support the FACS data that indicated little influx or
activation of NK cells in mock-treated tumor-bearing mice.
Surprisingly, however, while Sin/LacZ treated SCID mice
responded well to the treatment, the response to Sin/LacZ in
SCID/beige mice was greatly reduced, as indicated by tumor
growth (Fig. 3A and B) and survival (Fig. 3C). Indeed, in SCID/
beige mice, the enhanced survival following Sin/LacZ treatment
was not statistically significant, while survival was significantly
enhanced in similarly treated SCID mice. These results indicate
that NK cells play an important role in the efficacy of Sin/LacZ
treatment in this model.
The efficacy of Sin/LacZ treatment is greatly reduced
when NK cells are depleted
To verify that the results of the SCID/beige experiment were
due to NK cell deficiency, the experiment was repeated using
SCID mice that were depleted of NK cells. NK cells were depleted
using a monoclonal anti-CD122 Ab, which has been used in
previous studies [23]. First, to gauge the degree of NK depletion,
we compared the number of NK cells in the peritoneum of anti-
CD122-treated (NK depleted) vs. isotype-treated mice. NKp46
was used to identify NK cells rather than CD122, because of the
possibility that CD122 would be blocked by the Ab treatment. As
seen in Fig. 4A, the depletion of NK cells was effective. Notably,
other cells, like monocytes and macrophages, were not depleted by
anti-CD122 (Fig. S2).
For the therapeutic experiment, ES-2-bearing mice were
divided into two groups. One group received anti-CD122
injections to deplete their NK cells, while the other group received
control injections using a matched isotype control IgG. The
groups were further divided into Sin/LacZ-treated and mock-
treated groups. We observed that NK cell depletion had no
significant effect on tumor growth or survival of mock-treated mice
(Fig. 4B and C), again indicating that NK cells were not activated
by the ES-2 tumors. In contrast, the absence of NK cells had a
significant effect on Sin/LacZ-treated mice, with the efficacy of the
treatment being greatly reduced in the NK cell depleted group
(Fig. 4B). Survival results further confirmed this observation, as
NK depletion significantly reduced the survival of Sin/LacZ
treated mice (Fig. 4C). Nevertheless, Sin/LacZ treatment did
appear to retain some therapeutic effect even in the absence of NK
cells, indicating that Sin/LacZ efficacy is not be entirely NK cell
dependent.
To confirm that the depletion of NK cells, rather than an
artifact of using anti-CD122, is responsible for these results, we
also used anti-asialo GM1 Abs to deplete NK cells [24], and
obtained similar results (data not shown). Taken together, three
separate models of NK cell deficiency have demonstrated that the
efficacy of Sin/LacZ treatment in this model is largely, though not
completely, NK cell dependent.
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20598Figure 1. Changes in peritoneal immune cell populations in response to Sindbis/lacZ treatment in ES-2-bearing mice. (A) Top panel:
ES-2 bearing mice were treated i.p. daily for two days with Sindbis/LacZ (Sin/LacZ) or media (Mock). On day 3, mice were euthanized, and cells
harvested from the peritoneal cavity were analyzed by FACS as indicated. Only immune cells (CD45+ cells) were analyzed. Bottom panel:
Quantification of the results from the top panel, as described in Materials and Methods; Data for A is representative of 4–5 independent experiments
(n=14–16). (B) The kinetics of changes in various peritoneal immune cell populations in ES-2 bearing mice in response to Sin/LacZ treatment are
shown. Treatment started 4 days after tumor inoculation (designated day 0), and mice were treated 4 times a week. At each time point (0 h/
untreated, 3 h, 18 h, 48 h, day 5, day 7, and day 13), 2–4 mice from each group were euthanized and immune cell populations were quantified as in
A. Data for 0 h, 3 h, and 18 h is from one experiment; data for day 5, day 7, and day 13 is from one independent experiment per time point. Error bars
represent SEM. NS =not significant.
doi:10.1371/journal.pone.0020598.g001
Activation of NK Cells by Sindbis Vectors
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20598The efficacy of Sin/LacZ treatment is enhanced when
syngeneic NK cells are pre-injected into the mice
We have shown that Sin/LacZ can activate NK cells against
ES-2 tumors in SCID mice (Fig. 3 and 4A, B and C). Next, we
wanted to determine if the therapeutic effect of Sin/LacZ could be
enhanced by the addition of syngeneic NK cells. To test this, NK
cells were isolated from the spleens of tumor-free untreated mice,
and injected into mice retro-orbitally 2 hours before the first Sin/
LacZ treatment. Tumor growth was monitored using IVIS, and
was not significantly affected by the addition of NK cells (data not
shown). However, the survival of mice treated with Sin/LacZ +
NK cells was improved compared to mice treated with Sin/LacZ
alone (Fig. 4D).
The efficacy of Sin/IL12 treatment is also NK cell
dependent
Our previous results have demonstrated that SV vectors
carrying IL12 have greater therapeutic efficacy than Sin/LacZ
in the ES-2 tumor model [19]. In order to determine the role
of NK cells in this increased efficacy, the experiments shown in
Fig. 1 and 4 were repeated with Sin/IL12-treated mice in
addition to Sin/LacZ–treated mice. FACS analysis of cells
harvested by peritoneal lavage from Sin/IL12-treated mice
showed that Sin/IL12 induced a similar influx of NK cells as
Sin/LacZ (Fig. 5A). NK cell depletion experiments using anti-
CD122 and anti-asialo GM1 demonstrated that the therapeu-
tic effect of both Sin/LacZ and Sin/IL12 was largely
abrogated in the absence of NK cells (Fig. 5B). Notably, the
therapeutic enhancement obtained from Sin/IL12 compared
to Sin/LacZ (Fig 5B; left panel) was also essentially eliminated
in the absence of NK cells (right panels), demonstrating that
the enhanced efficacy of Sin/IL12 was also NK cell-
dependent.
It should be noted, that in SCID/beige mice, Sin/IL12 retained
a moderate therapeutic effect (Fig. S3A), and FACS analysis
revealed that there was a strong influx of NK cells in SCID/beige
mice treated with Sin/IL12 (Fig. S3B). As mentioned, SCID/beige
mice have a deficiency in NK cell cytotoxicity. However, they still
have NK cells, which retain some regulatory functions, like the
ability to secrete IFNc in response to IL12.
The enhanced therapeutic effect from Sin/IL12 is IFNc-
dependent
IL12 can induce the secretion of IFNc from NK cells [25]. Since
we determined that the enhanced efficacy of Sin/IL12 is NK cell
dependent (Fig. 5B), we hypothesized that IFNc secretion by NK
cells might be involved in this therapeutic enhancement. To test
this, we measured IFNc levels in the peritoneum of Sin/LacZ,
Sin/IL12, and mock-treated ES-2-bearing mice. We determined
that both mock-treated and Sin/LacZ-treated mice have almost
no peritoneal IFNc 24 h or 48 h after treatment was started. In
contrast, Sin/IL12-treated mice had high levels of IFNc in the
peritoneum at 48 h (Fig. 6A, left panel). To verify that the source
of IFNc was Sin/IL12-activated NK cells, we repeated the IFNc
assay in Sin/IL12-treated mice that were depleted of NK cells,
and confirmed that in the absence of NK cells, Sin/IL12 did not
induce the secretion of IFNc in the peritoneum (Fig. 6A, right
panel).
In order to determine if Sin/LacZ and/or Sin/IL12
treatment efficacy is dependent on IFNc, we repeated the
therapeutic experiments described above, and added additional
groups in which IFNc activity was blocked with a monoclonal
Ab. As expected, blocking IFNc had no effect on Sin/LacZ
treatment. However, it did reduce the efficacy of Sin/IL12
treatment (Fig. 6B). Survival results indicated that in the
absence of IFNc, Sin/IL12 treatment is comparable to Sin/
LacZ treatment (Fig. 6B, right panel), further suggesting that
IFNc is responsible for the increased efficacy obtained from
Sin/IL12 treatment.
Figure 2. Activation of peritoneal NK cells in ES-2-bearing mice
in response to Sin/LacZ treatment. (A) 48 h after the first of 2 daily
i.p. Sin/LacZ treatments, the size (forward scatter; FSC) and the
granularity (side scatter; SSC) of peritoneal NK cells from Sin/LacZ
treated mice (black lines) was compared to peritoneal NK cells from
mock-treated mice (solid grey). Data is representative of 5 independent
experiments (n=16). (B) Using the same annotation as in A, the
expression of early activation marker CD69 on peritoneal NK cells from
Sin/LacZ vs. mock-treated mice is shown. 18 h and 24 h samples were
taken after one treatment; 48 h samples were taken after 2 treatments;
each time point represents an independent experiment (n=3 per
experiment). (C) Expression of NKG2D, FasL, and Trail on NK cells 48 h
after the first of 2 daily i.p. Sin/LacZ treatments; data is representative of
2 independent experiments for NKG2D (n=5 combined), and one
experiment for FasL and Trail (n=2). (D) The cytotoxicity of peritoneal
NK cells from Sin/LacZ-treated mice was determined by incubation of
peritoneal NK cells from Sin/LacZ-treated mice or splenic NK cells from
mock-treated mice with YAC-1 cells, as described in materials and
methods; data is representative of 2 independent experiments.
doi:10.1371/journal.pone.0020598.g002
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upregulation of MHC class II expression on peritoneal
macrophages
Because IL12 is a known Th1 cytokine [26], we wanted to
determine if Sin/IL12 could influence macrophages in the tumor
environment by shifting them towards an M1 anti-cancer
phenotype. We also wanted to determine if NK cells are involved
in the activation of peritoneal macrophages. To do this, we
repeated the Sin/LacZ and Sin/IL12 NK cell depletion
experiment, but terminated the experiment after 1 week, at which
point the mice were sacrificed and cells harvested from the
peritoneum were analyzed. To determine the expression of the M1
marker MHC class II on macrophages, we stained peritoneal cells
with Abs against the macrophage marker F4/80 and MHC class
II. We determined that Sin/LacZ induced only a minor increase
in MHC II expression on macrophages, but Sin/IL12 induced a
much greater increase (Fig. 7A). Notably, depleting NK cells
largely inhibited the increase in MHC II (Fig. 7A).
IFNc has been shown to induce the expression of MHC class II
on macrophages in some models [27]. Because we determined that
NK cells secrete IFNc in response to Sin/IL12 (Fig. 6A), and
because the expression of MHC class II on peritoneal macro-
phages in response to Sin/IL12 was NK cell dependent (Fig. 7A),
we wanted to determine if IFNc is responsible for the increase in
MHC class II. To do this, we treated tumor-bearing mice with
media (mock), Sin/LacZ, Sin/IL12, Sin/IL12 + anti- IFNc (to
block IFNc activity), or Sin/IL12 + anti-CD122 (to deplete NK
cells). After two consecutive treatments (one per day), we sacrificed
the mice (on the third day), and analyzed the peritoneal
macrophage population. We determined that the Sin/IL12-
dependent induction of MHC class II expression on macrophages
was abolished in absence of IFNc or NK cells (Fig. 7B).
Discussion
Clinical studies have demonstrated that OV anti-cancer efficacy
in mouse models doesn’t always translate well to human patients.
One possible reason for this discrepancy is an incomplete
understanding of the mechanism behind the successful results in
mice. Most OVs were originally identified by their ability to
preferentially kill cancer cells in vitro [6]. As a result, the
therapeutic efficacy of OV treatments in vivo has traditionally
been attributed to direct viral oncolysis. Advances in animal
imaging techniques have enabled researchers to demonstrate
tumor-specific targeting of human and mouse tumors by a few
OVs [18,28], further supporting the direct viral oncolysis
hypothesis. However, in some cases, effective OV cancer therapy
did not require progressive replication and oncolysis [29], or was
achieved even in tumor models that are not efficiently lysed by the
OV in vitro [30], pointing to a possible indirect anti-cancer effect.
In the last few years, studies in immunocompetent mouse models
have demonstrated an important role for immune cell activation in
several OV therapies [2,9,10]. Recently, innate immune responses
in xenograft OV models have also been reported [30,31,32],
however, the therapeutic relevance of these responses has not been
Figure 3. Sin/LacZ anti-ES-2 efficacy is significantly reduced in mice deficient in NK cell cytotoxicity. (A) ES-2 bearing SCID mice or SCID/
beige mice were treated i.p. starting on day 3, 4 times a week, for 2 weeks, with Sin/LacZ (n=5) or media (n=5), and the effect of the treatment on
tumor growth was monitored using IVIS. Images were taken on days 2 (one day before the treatment started), 6, 10 and 16. Representative images
are shown. (B) Tumor growth from the experiment shown in A was determined by quantifying whole mouse luminescence for each individual mouse;
the luminescence was then divided by the day 2 luminescence of the same mouse, to determine the fold change (relative tumor growth). Shown is
the average fold change for each group (n=5). For A and B, data from one representative of 2 independent experiments is shown. (C) Kaplan-Meier
survival plots from 2 independent experiments, one of which is shown in A and B, were combined (n=8). Error bars represent SEM.
doi:10.1371/journal.pone.0020598.g003
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immune responses, and in particular NK cells, are involved in the
therapeutic efficacy of SV therapy in a well-established xenograft
model for ovarian cancer.
NK cell cytotoxicity is activated by the interactions between
activating receptors on the NK cells with stress ligands on target
cells, and by the absence of interactions between inhibitory
receptors on the NK cells with MHC class I molecules on target
cells [12]. Both virally infected cells and cancer cells can
potentially upregulate stress ligands [12,33], and downregulate
MHC class I [12,34], marking them for NK cell mediated lysis.
However, for an effective NK response to occur, peripheral NK
cells need to be activated and recruited to the site of infection/
tumor. Moreover, in the case of cancer, tumor-induced immuno-
suppression often needs to be overcome. The current study
provides proof of concept that (i) Sin/LacZ treatment can activate
NK cells and recruit them to the tumor environment, where their
cytolytic function is redirected against ES-2 tumor cells, and (ii)
Sin/IL12 treatment can modulate the regulatory functions of NK
cells, resulting in the induction of anti-cancer M1 macrophages,
which can potentially reverse cancer-induced immunosuppression.
The immune response to viral infections is triggered by the
recognition of viral pathogen-associated molecular patterns
(PAMPs) [35] or by danger signals generated by virally induced
tissue damage [36], and results in the recruitment and activation of
a large number of effector cells at the site of infection. Cancer cells
lack PAMPs, and often don’t induce a strong danger signal [37],
resulting in poor immune cell activation. In this study, we show
that SV-activated NK cells are recruited to the peritoneum of
SCID mice, where they target and kill i.p. growing ES-2 tumors.
The influx of NK cells into the peritoneum, and their activation as
demonstrated by an increase in size and granularity, are
independent of the ES-2 tumor cells, and also occur in tumor-
free mice that were treated with SV. Furthermore, SV-activated
peritoneal NK cells can also lyse Yac-1 cells, suggesting a general
activation of NK cell cytotoxicity rather than a response against
the xenograft. Indeed, in the absence of SV, ES-2 tumors do not
induce the activation or the influx of NK cells.
Figure 4. Sin/LacZ efficacy is reduced in mice depleted of NK cells, and enhanced in mice augmented with NK cells. (A) FACS analysis
of cells harvested from the peritoneum of Sin/LacZ-treated and mock-treated ES-2 bearing mice that were injected with anti-CD122, or with an
isotype control Ab (IgG), shows the depletion NK cells (NKp46+ SSC low) in response to the anti-CD122 treatment; data is representative of 2
independent experiments (n=5). (B) The effect of NK cell depletion using anti-CD122 on tumor growth in Sin/LacZ and mock-treated mice is shown.
The treatment scheme was similar to figure 3, but treatment and imaging started on day 4. Quantification was done as explained in figure 3; data is
representative of 3 independent experiments (n=12). (C) Kaplan-Meier survival plots from 2 independent experiments were combined (n=7). (D)
SCID mice were treated with media, Sin/LacZ or Sin/LacZ +6610
5 syngeneic NK cells (one retro-orbital injection 2 h before the first Sin/LacZ
treatment), and their survival was plotted. Data is from one experiment (n=4). Sin/LacZ treatments were administered 4 times a week for 2 weeks, as
in previous experiments. Error bars represent SEM.
doi:10.1371/journal.pone.0020598.g004
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foreign tissues, and might therefore be particularly susceptible to
SV-activated NK cells. This reveals a general limitation of this
mouse model, and might explain the high efficacy observed in other
OV xenograft models in which the role of NK cells has not yet been
examined. For example, it has previously been reported that
replication-competent Sindbis has an anti-cancer effect in a
peritoneal dissemination model for ovarian cancer [38]. In that
study, Sindbis was able to inhibit the abdominal swelling that results
from ascites formation in nude mice bearing human OMC-3
tumors. These effects are similar to what we have observed in our
ES-2 model using replication deficient SV vectors (Fig 3A, Day 16,
and additional unpublished results). However, in the absence of
functional NK cells, the inhibition of abdominal swelling is greatly
reduced, indicating that SV-activated NK cells are largely
responsible for this therapeutic effect in our model. Notably, we
have previously shown that SV-dependent inhibition of abdominal
swellingalsooccurredinimmunocompetentmicebearingsyngeneic
ovarian tumors [19]. Additional studies areneeded to determine the
role of SV-activated NK cells in that model.
Another limitation of SCID mouse models is the absence of
regulatory T cells and other factors that can generate an
immunosuppressive tumor environment. It is not clear if SV
treatment alone can overcome this suppression, which can inhibit
NK cell function [39]. One way to potentially increase the ability
of SV-activated NK cells to work in an immunosuppressive
environment is by engineering a Sindbis vector that can deliver
specific immune modulators to the tumor environment. IL12 is a
potent cytokine, which can have numerous effects on tumor
growth, including activation of NK cells, and the induction of
IFNc [40]. SV vectors carrying IL12 have been shown to have an
enhanced therapeutic effect, but the mechanism has not been
Figure 5. The efficacy of Sin/IL12 treatment is also dependent on NK cells. (A) Left panel: FACS analysis of peritoneal samples from mock,
Sin/LacZ, or Sin/IL12-treated ES-2-bearing mice shows the percentage of NK cells (CD122+ SSC low) within the CD45+ (immune cell) gate 48 h after
the first of two daily Sin/LacZ or Sin/IL12 treatments. Data is representative of one experiment (n=4). Right panel: kinetics of the change in peritoneal
NK cell numbers in response to the treatment. Four time points (days 0/untreated, 1, 2, and 7) are shown (n=2–4 for each time point). (B) The
experiment shown in figure 4B and C was repeated, adding Sin/IL12-treated mice. NK cells were depleted with either anti-CD122 (middle panels) or
anti-Asialo GM1 (right panels). Tumor growth and survival were monitored, quantified and plotted as in figure 4. Data is representative of one
experiment (n=3–4, as shown). Error bars represent SEM.
doi:10.1371/journal.pone.0020598.g005
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but not Sin/LacZ-activated NK cells, secrete IFNc, and that IFNc
plays a critical role in the enhanced therapeutic effect obtained
from Sin/IL12.
IFNc can exert anti-cancer effects in several different ways [41].
Ovarian cancer requires angiogenesis to grow, so the antiangio-
genic effects of IFNc [42] are one possible therapeutic mechanism.
Another appealing function of IFNc is its influence on tumor-
associated macrophages, which are often immunosuppressive [43].
As a key Th1 cytokine, IFNc can shift the tumor-associated
macrophage population towards the M1 anti-cancer phenotype.
In one report, IFNc and double stranded RNA, a viral PAMP,
have been shown to individually and additively activate macro-
phages [44]. In our model, Sin/IL12, but not Sin/LacZ or Sin/
IL12 + IFNc blockade, induced the expression of the M1
activation marker MHC class II on peritoneal macrophages.
Notably, this induction was NK cell dependent, demonstrating
that SV vectors can activate the regulatory function of NK cells as
well as their cytotoxicity. NK cells have also been reported to
provide IFNc for Th1 priming in an immunocompetent mouse
model [45]. Further studies are needed to determine the effect of
Sin/IL12 therapy on T cell activity.
Figure 6. The enhanced therapeutic effect of Sin/IL12 compared to Sin/LacZ is IFNc dependent. (A) Left panel: ES-2 bearing mice were
treated daily for two days with Sin/LacZ, Sin/IL12, or media. After 24 h (one treatment), or 48 h (two treatments), mice were euthanized, and their
peritoneum was washed with HBSS. IFNc levels in the peritoneal washes was determined by ELISA. Data is from one experiment per time point
(n=2–3 as indicated). Right panel: The experiment was repeated, and an additional group in which NK cells were depleted using anti-CD122 was
added. Data is from one experiment (n=4). (B) ES-2 bearing mice were treated with media, Sin/LacZ, Sin/IL12, Sin/LacZ + anti-IFNc (to block IFNc
activity) or Sin/IL12 + anti-IFNc. The effect of the IFNc blockade was determined by monitoring tumor growth and mouse survival, as explained in
previous figures. Data is representative of 2 independent experiments, as shown (n=4 for experiment 1; n=2–3 for experiment 2). Error bars
represent SEM.
doi:10.1371/journal.pone.0020598.g006
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influence tumor cells directly, for example, by inducing the
expression of stress markers, thereby making them more
susceptible to effector cell mediated lysis [46,47]. However, if
OV infection by itself results in the death of infected cells, as is
often the case, then effector cell mediated lysis of infected tumor
cells is redundant and not therapeutic. SV infection results in the
induction of apoptosis in mammalian cells [48,49], including ES-2
cells (our unpublished results). We have demonstrated that NK
cells are responsible for most of the therapeutic efficacy of SV,
therefore it seems likely that SV-activated NK cells can also target
uninfected ES-2 cells. One of the limitations of using replication
defective vectors, which are safer, is low infectivity, because the
virus cannot replicate inside the tumor. However, our results
suggest that SV treatment results in a strong NK cell-mediated
bystander effect, demonstrating that high infectivity might not
always be required for effective OV therapy.
Ironically, another consequence of using replication competent
vectors is that their propagation could be inhibited by NK cell-
mediated lysis of infected cells, as has been recently reported [50].
In that study, in which vesicular stomatitis virus vectors were used
for cancer therapy in immunocompetent rats bearing hepatocel-
lular carcinoma, the inhibition of NK and NKT cells was
therapeutically beneficial. These results are in stark contrast to
other studies, including our current study, in which NK cell
inhibition is detrimental. Such discrepancies between OV studies
underscore the complexity of the interactions involved [2,5].
Ultimately, the role of NK cell activation in OV therapy will
depend on the properties of the OV and on the particular cancer
being treated, in addition to any underlying differences in NK cell
function between patients.
Based on the results of this study, we propose a model for NK
cell activation by SV vectors (Fig. 8). We have previously shown
that treatment with Sin/LacZ (middle panel) results in the
infection of ES-2 cells [19]. However, the signals initiating NK
cell recruitment and activation originate in host cells, because
these events also occur in tumor-free mice. NK cell recruitment
and activation likely involves the secretion of danger signals or
exposure to viral PAMPs, but additional studies are needed to
elucidate the precise mechanism. Sin/IL12 treatment also
induces the recruitment and activation of NK cells, but in
addition, it results in the production and secretion of IL12 from
Figure 7. Sin/IL12 induces the NK cell-dependent, IFNc-dependent expression of MHC class II on peritoneal macrophages. (A) ES-2
bearing mice were treated for one week (4 treatments) with media, Sin/LacZ, Sin/LacZ + anti-CD122 (NK cell depleted), Sin/IL12, or Sin/IL12 + anti-
CD122, after which mice were euthanized, and the expression of MHC class II on peritoneal macrophages (F4/80+ FSC high cells) was analyzed by
FACS (left panel), and quantified (right panel) (n=2–3 as shown). Black lines represent NK cells from the various Sindbis-treated mice, and the solid
grey curve represents NK cells from mock-treated mice. (B) ES-2 bearing mice were treated daily for two days with media, Sin/LacZ, Sin/IL12, Sin/IL12
+ anti-IFNc (IFNc block), or Sin/IL12 + anti-CD122 (NK cell depleted). MHC expression was analyzed and quantified as in A. Data is from one
experiment (n=4).
doi:10.1371/journal.pone.0020598.g007
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activated NK cells in the peritoneum, resulting in an enhanced
therapeutic effect, and in the upregulation of the M1 marker
MHC class II on peritoneal macrophages (right panel). We have
not yet determined if the activation of macrophages is
responsible for the therapeutic effect induced by Sin/IL12-
dependent IFNc. However, the induction of M1 macrophages is
a key step in reducing the immunosuppressive influence of the
tumor environment, and is therefore a central goal of
immunotherapy.
Cancer is the result of the accumulation of multiple defects in
cell regulation and behavior, making it difficult to combat the
disease with simple therapeutic regimens. Consequently, novel and
combinatorial treatments are sought that can target tumor growth
from different directions, reducing the likelihood of treatment
resistance. By better understanding the role of immune activation
by SV vectors, we can better predict possible positive (or negative)
interactions between SV treatment and other therapies. For
example, we can attempt to induce a synergistic effect by
combining SV with other immunotherapeutic agents, like
cytokines or autologous NK cells. Alternatively, we can seek a
non-overlapping additive effect by activating immune cells with
SV, while killing tumor cells directly with chemotherapy and SV-
induced apoptosis. The immunosuppressive functions of some
chemotherapeutic agents also need to be considered, to avoid
possible antagonistic effects. However, ‘targeted immunosuppres-
sion’ could in theory be beneficial, if it can inhibit the immune
response to the virus (and therefore increase direct viral oncolysis)
without significantly suppressing the immune response against the
tumor.
The significance of this study is that it provides a proof-of-
principle for NK cell activation by SV vectors. Additional studies
are needed to compliment these results. The SCID model used
here demonstrates that NK cell activation by SV vectors is
possible, and therefore presents us with a novel goal for
enhancing OV therapy using SV vectors. Future studies with
immunocompetent models will determine whether or not T cells
or B cells interfere or support the activation of NK cells by SV
vectors, and in the process, may provide us with valuable
information as to what is needed for effective NK cell activation
in these models. In vitro studies using human immune cells will
also complement our current study, revealing any interspecies
differences between humans and mice, and laying the ground for
future clinical studies.
Figure 8. Model for the activation of NK cells by Sindbis vectors. Left panel: ES-2 cells are not susceptible to resting NK cells, and cannot
activate or recruit NK cells. Middle panel: Sin/LacZ targets ES-2 cells, inducing apoptosis of infected cells. At the same time, viral PAMPs and/or virus-
induced danger signals lead to the recruitment and activation of NK cells at the tumor site. Sin/LacZ-activated NK cells target and lyse ES-2 cells,
including uninfected cells (bystander effect). Right panel: Sin/IL12 activates and recruits NK cells by the same mechanism as Sin/LacZ, but in addition,
leads to the secretion of IL12 from ES-2 cells, which induces the secretion of IFNc from NK cells, resulting in the activation of peritoneal macrophages
and an enhanced therapeutic effect.
doi:10.1371/journal.pone.0020598.g008
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Figure S1 Sin/LacZ induces the influx of NK cells into
the peritoneum, and an increase in peritoneal NK cell
granularity in tumor-free mice. The experiment shown in
Fig 1.A was repeated in tumor-free mice. Top panel: represen-
tative FACS plots from 2 independent experiments (n=6). Bottom
panel: quantification of the cell populations. Error bars represent
SEM.
(TIF)
Figure S2 The effect of anti-CD122 injections on the
peritoneal immune cell populations in Sin/LacZ-treated
ES-2-bearing SCID mice. Mice were treated with Sin/LacZ
for one week (for a total of 4 injections), and were injected with
anti-CD122 or no Ab every 2–3 days starting one day before the
first Sin/LacZ treatment. Top panel: representative FACS plots
from one experiment (n=3). Bottom panel: quantification of the
cell populations.
(TIF)
Figure S3 The effect of Sin/IL12 treatment on SCID/
beige mice bearing ES-2 tumors. (A) ES-2 bearing SCID/
beige mice were treated i.p. starting day 3, 4 times a week, for 2
weeks, with Sin/LacZ, Sin/IL12 or media, and the effect of the
treatment on tumor growth was monitored using IVIS as in
figure 3 (n=5). B. Top: Mice were treated with media, Sin/LacZ
or Sin/IL12 on days 4, 5, 8, 9, and 10 after ES-2 inoculation, and
were euthanized on day 12, after which peritoneal cells were
harvested and analyzed by FACS. Bottom: Quantification of the
peritoneal NK cell populations from the top panel. Data is from
one experiment (n=2).
(TIF)
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